Efficacy and safety of rituximab in patients with multiple sclerosis : An observational study at a tertiary center in Makkah, Saudi Arabia
Copyright: © Neurosciences..
OBJECTIVES: To assess the efficacy and safety of rituximab for multiple sclerosis (MS) treatment in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score and adverse events.
METHODS: This is a retrospective cross-sectional study conducted at King Abdullah Medical City, from January 2017 to August 2021, involving patients with MS given rituximab, with 1-year follow-up. Clinical parameters were noted pre- and post-treatment to determine efficacy; adverse events were noted to analyze safety. A paired samples t-test was used to compare responses pre- and post-treatment. A p-value<0.05 was considered significant.
RESULTS: Among 31 patients, 6 (19.4%) had progressive MS, and 25 (80.6%) had relapsing-remitting MS (mean disease duration=8.12±5.65 years). The annual relapse rate reduced from 1.67±0.97 to 0.06±0.25 (p<0.001), the EDSS score from 3.16±2.14 to 2.80±2.28 (p=0.141) and the MRI activity score from 1.84±1.03 to 1.03±0.18 (p<0.001). Only one patient had enhancing lesion activity post-treatment. The commonest side effect was urinary tract infection (25.8%). Only 2 patients discontinued the drug.
CONCLUSION: Rituximab is an efficient drug in reducing the annual relapse rate and MRI activity of patients with MS, with few tolerable side effects not leading to drug discontinuation or any lethal outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Neurosciences (Riyadh, Saudi Arabia) - 27(2022), 2 vom: 01. Apr., Seite 65-70 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Almatrafi, Yassir M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 29.04.2022 Date Revised 16.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.17712/nsj.2022.2.20210122 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340067993 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340067993 | ||
| 003 | DE-627 | ||
| 005 | 20231226004317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.17712/nsj.2022.2.20210122 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340067993 | ||
| 035 | |a (NLM)35477910 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Almatrafi, Yassir M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of rituximab in patients with multiple sclerosis |b An observational study at a tertiary center in Makkah, Saudi Arabia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © Neurosciences. | ||
| 520 | |a OBJECTIVES: To assess the efficacy and safety of rituximab for multiple sclerosis (MS) treatment in terms of reduction in clinical relapses, magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score and adverse events | ||
| 520 | |a METHODS: This is a retrospective cross-sectional study conducted at King Abdullah Medical City, from January 2017 to August 2021, involving patients with MS given rituximab, with 1-year follow-up. Clinical parameters were noted pre- and post-treatment to determine efficacy; adverse events were noted to analyze safety. A paired samples t-test was used to compare responses pre- and post-treatment. A p-value<0.05 was considered significant | ||
| 520 | |a RESULTS: Among 31 patients, 6 (19.4%) had progressive MS, and 25 (80.6%) had relapsing-remitting MS (mean disease duration=8.12±5.65 years). The annual relapse rate reduced from 1.67±0.97 to 0.06±0.25 (p<0.001), the EDSS score from 3.16±2.14 to 2.80±2.28 (p=0.141) and the MRI activity score from 1.84±1.03 to 1.03±0.18 (p<0.001). Only one patient had enhancing lesion activity post-treatment. The commonest side effect was urinary tract infection (25.8%). Only 2 patients discontinued the drug | ||
| 520 | |a CONCLUSION: Rituximab is an efficient drug in reducing the annual relapse rate and MRI activity of patients with MS, with few tolerable side effects not leading to drug discontinuation or any lethal outcome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Babakkor, Mohammed A |e verfasserin |4 aut | |
| 700 | 1 | |a Irfan, Muhammed |e verfasserin |4 aut | |
| 700 | 1 | |a Samkari, Ebaa T |e verfasserin |4 aut | |
| 700 | 1 | |a Alzahrani, Waleed M |e verfasserin |4 aut | |
| 700 | 1 | |a Mohorjy, Doaa K |e verfasserin |4 aut | |
| 700 | 1 | |a Zahoor, Sarmad |e verfasserin |4 aut | |
| 700 | 1 | |a Farooq, Muhammad T |e verfasserin |4 aut | |
| 700 | 1 | |a Sajid Jehangir, Hafiz M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurosciences (Riyadh, Saudi Arabia) |d 2000 |g 27(2022), 2 vom: 01. Apr., Seite 65-70 |w (DE-627)NLM199964181 |x 1319-6138 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:2 |g day:01 |g month:04 |g pages:65-70 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17712/nsj.2022.2.20210122 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 2 |b 01 |c 04 |h 65-70 | ||